key: cord-0730942-y89shoj4
authors: Kollias, Anastasios; Kyriakoulis, Konstantinos G; Stergiou, George S; Syrigos, Konstantinos
title: Heterogeneity in reporting venous thromboembolic phenotypes in COVID‐19: Methodological issues and clinical implications
date: 2020-07-04
journal: Br J Haematol
DOI: 10.1111/bjh.16993
sha: 1605ca669cd3ee56b3c55f8670bb4b9c1d2386b2
doc_id: 730942
cord_uid: y89shoj4

COVID‐19 is associated with increased risk of venous thromboembolic events (VTE). However, there is significant heterogeneity in the thromboembolic phenotypes of COVID‐19 patients (deep vein thrombosis, pulmonary embolism/thrombosis). The latter might be partly attributed to the variation in VTE risk factors in COVID‐19 patients including: (i) patients’ characteristics; (ii) hospitalization conditions and interventions; (iii) SARS‐Cov‐2 specific factors (coagulopathy, endothelial injury/microthrombosis). Furthermore, there is methodological heterogeneity in relation to the assessment of VTE (indications for screening, diagnostic methodology, etc). Physicians should be aware of the increased VTE risk, strongly consider VTE screening, and use thromboprophylaxis in all hospitalized patients.

Accumulating evidence suggests that severe coronavirus disease 2019 (COVID-19) is associated with an increased venous thromboembolic risk. 1, 2 It appears that SARS-CoV-2 in severe cases induces an excessive immune response associated with cytokine storm leading in turn to coagulation disorders. 1.2 The latter can be observed at both local level with lung endothelial injury and microthothrombosis, as well as at systematic level with disseminated intravascular coagulopathy. 1, 2 In light of the emerging evidence on the thromboembolic risk in COVID-19, recent publications highlight 2 important issues: First the high rate of venous thromboembolism events (VTE) in COVID-19 patients, and second the variety of the observed thromboembolic phenotypes. Indeed, 11 recent studies reported both the prevalence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in COVID-19 patients with prevalence numbers ranging from 0% to as high as 54% ( Table 1) . [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Importantly, there was no consistent relationship between the reported prevalence of DVT and PE. It should be mentioned that most studies have included mainly patients in intensive care unit (ICU) who presumably had severe COVID-19 (Table 1 ). One study reported that the prevalence of VTE was significantly higher in ICU versus general ward patients (47% and 3% respectively). 6 These data indicate that there is heterogeneity in the reported VTE risk -although recognized by all as increased -as well as in the thromboembolic phenotypes of COVID-19 patients (isolated DVT, isolated pulmonary embolism/thrombosis, concurrent DVT and pulmonary embolism/thrombosis). It might be suggested that variation in several VTE risk factors in COVID-19 patients accounts for this observed heterogeneity which are presented in Figure 1 and include: 

This article is protected by copyright. All rights reserved pulmonary angiography or both, which is largely dependent on the available human and equipment resources.

Interestingly, even in studies which reported screening for DVT with leg compression ultrasonography in all their patients, there has been significant heterogeneity. Specifically, Ren et al reported that among 48 critically ill COVID-19 patients hospitalized in the ICU, 41 (85%) presented with lower extremity DVT, mainly in the pattern of isolated distal DVT. 14 On the contrary, in another study in 64 COVID-19 patients hospitalized in general ward, none was found with DVT. 15 The two studies included patients with similar age (median 70 years) and gender distribution, yet the former study included patients admitted in ICU with a more severe disease and 7-fold higher d-dimer levels. 14, 15 It should be mentioned that thromboprophylaxis was administered in both studies. 14,15 In summary, and in terms of clinical practice, physicians dealing with COVID-19 patients should be aware that: (i) The risk of venous thromboembolism is high, yet with variable incidence of phenotypes (DVT and PE); (ii) All hospitalized patients require thromboprophylaxis, yet the optimal dosing is uncertain; (iii) VTE screening should be strongly considered and influenced by clinical and biochemical characteristics (d-dimer).

AK and KGK performed the research and drafted the manuscript GSG, KS provided critical review and supervision This article is protected by copyright. All rights reserved 

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

Thrombotic risk in COVID-19: a case series and case-control study

Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection

Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom

Incidence of venous thromboembolism in hospitalized patients with COVID-19

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence

Thrombotic events in SARS-CoV

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan

Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Thromb Haemost

This article is protected by copyright. All rights reserved